ストックスクリーナーアプリを入手
24.65
0.74%
0.18
前日終値:
$24.47
開ける：
$24.47
24時間の取引高:
450.10K
Relative Volume:
0.51
時価総額：
$1.16B
収益：
$681.75M
当期純損益:
$70.47M
株価収益率:
17.00
EPS:
1.45
ネットキャッシュフロー:
$173.19M
1週間 パフォーマンス:
+4.05%
1か月 パフォーマンス:
+5.75%
6か月 パフォーマンス:
+45.43%
1年 パフォーマンス:
-7.92%
1日の値動き範囲:
$24.33
$25.08
1週間の範囲:
$23.62
$25.35
52週間の値動き範囲:
$11.16
$31.67
Pacira Biosciences Inc Stock (PCRX) Company Profile
名前
Pacira Biosciences Inc
セクター
電話
813-553-6680
住所
5401 WEST KENNEDY BOULEVARD, TAMPA, NJ
PCRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
24.65 | 1.16B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-30 | アップグレード | Truist | Sell → Hold |
| 2024-08-13 | ダウングレード | Truist | Buy → Sell |
| 2024-08-12 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2024-08-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-03-07 | 再開されました | JP Morgan | Overweight |
| 2023-12-20 | 開始されました | Raymond James | Outperform |
| 2023-08-03 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | 再開されました | Wedbush | Outperform |
| 2022-10-21 | 再開されました | Jefferies | Buy |
| 2022-01-03 | 再開されました | JP Morgan | Overweight |
| 2021-07-26 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-04-21 | 再開されました | JP Morgan | Neutral |
| 2021-04-09 | 開始されました | Berenberg | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2021-02-11 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | 繰り返されました | Needham | Buy |
| 2020-05-27 | 開始されました | Guggenheim | Neutral |
| 2020-04-07 | 開始されました | Northland Capital | Outperform |
| 2020-03-20 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-24 | 開始されました | SunTrust | Buy |
| 2020-01-23 | 開始されました | SunTrust | Buy |
| 2019-11-06 | 開始されました | BTIG Research | Buy |
| 2019-06-11 | 開始されました | Barclays | Overweight |
| 2019-05-06 | アップグレード | Mizuho | Underperform → Neutral |
| 2019-05-02 | アップグレード | Stifel | Sell → Hold |
| 2019-02-01 | ダウングレード | Mizuho | Neutral → Underperform |
| 2018-08-06 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-03-21 | 繰り返されました | Mizuho | Neutral |
| 2018-02-16 | ダウングレード | Needham | Buy → Hold |
| 2018-01-19 | 開始されました | Seaport Global Securities | Buy |
| 2018-01-04 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-01-03 | 開始されました | Leerink Partners | Mkt Perform |
すべてを表示
Pacira Biosciences Inc (PCRX) 最新ニュース
(PCRX) Investment Analysis and Advice - news.stocktradersdaily.com
Pacira (PCRX) Announces New $300M Share Repurchase Plan | PCRX Stock News - GuruFocus
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation - markets.businessinsider.com
Pacira Biosciences IncAuthorizes $300 Million Share Repurchase Program - marketscreener.com
Pacira Biosciences Approves $300M Share Buyback - MarketWatch
Pacira BioSciences initiates $300 million buyback plan - Investing.com
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders | PCRX Stock News - GuruFocus
Pacira BioSciences Announces $300M Share Buyback and '5x30' Growth Plan: Double-Digit Revenue Growth Targeted - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Connect - markets.businessinsider.com
Is Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth? - Yahoo Finance
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Reach Out - markets.businessinsider.com
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listin - GuruFocus
Raymond James Financial Inc. Acquires Shares of 10,099 Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule - MarketScreener
Pacira BioSciences (PCRX) Grants Inducement Awards to New Employ - GuruFocus
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Pacira's Latest Move: 66,500 Shares in Stock Awards Signal Aggressive Talent Push - Stock Titan
Sei Investments Co. Sells 7,231 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com
Taking the lead: Pacira BioSciences Inc (PCRX) - Sete News
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb - Yahoo Finance
Vanguard Group Inc. Decreases Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira Biosciences' SWOT analysis: stock outlook amid litigation settlement - Investing.com Australia
Pacira Biosciences' SWOT analysis: stock outlook amid litigation settlement By Investing.com - Investing.com South Africa
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More - Yahoo Finance
Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act - Seeking Alpha
Pacira (PCRX) Surges 14.7%: Is This an Indication of Further Gains? - Yahoo Finance
Pacira Biosciences’ SWOT analysis: stock outlook amid litigation settlement By Investing.com - Investing.com UK
Corebridge Financial Inc. Trims Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $27.22 Average Target Price from Analysts - The AM Reporter
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up After Analyst Upgrade - Defense World
Pacira Reaches IP Deal Allowing Generic Painkiller In 2030 - Law360
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation - markets.businessinsider.com
PCRX Stock Soars on Exparel Patent Settlement With Generic Players - Zacks Investment Research
Pacira Biosciences Stock Rises On Patent Litigation Settlement: Retail Sentiment Soars - MSN
Forecasting The Future: 8 Analyst Projections For Pacira BioSciences - Benzinga
Pacira Biosciences Resolves Patent Disputes, Shares Jump Over 21% - Finimize
RBC Raises Price Target on Pacira Biosciences to $26 From $22, Keeps Sector Perform Rating - MarketScreener
Truist Raises Price Target on Pacira Biosciences to $28 From $25, Keeps Hold Rating - MarketScreener
Pacira Biosciences Settles Patent Litigations Over Local Analgesic; Shares Rise Pre-bell - MarketScreener
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by American Century Companies Inc. - Defense World
Pacira BioSciences (PCRX) Shares Spike 15% After Patent Settleme - GuruFocus
Pacira surges on patent settlement with Fresenius - MSN
Pacira Pharmaceuticals Settles Patent Litigation with Fresenius - TipRanks
Pacira stock surges on patent settlement (PCRX:NASDAQ) - Seeking Alpha
Pacira Biosciences Announces Settlement Of U.S. Patent Litigation For Exparel - MarketScreener
Pacira BioSciences stock surges on patent litigation settlement By Investing.com - Investing.com Canada
Pacira BioSciences stock surges on patent litigation settlement - Investing.com Australia
Pacira Biosciences Inc (PCRX) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
0.80%
大文字化:
|
ボリューム (24 時間):